Healthcare / Elderly CareGlobal
← Sticker Wall
JOURNEY · DETAIL
Dentsply Sirona: A History of M&A from an 1899 Consumables Supplier to the Global Dental Leader
Founded: The founding team of Dentsply in 1899 and the independent team from Siemens Healthcare's dental division for Sirona. · Dentsply Sirona Inc.
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionGlobal
ScaleGiant
ChannelOther
Origin
Dentsply was founded in the U.S. in 1899 and officially claims over 130 years of dental innovation history, initially establishing itself through the distribution of dental consumables and supplies, which built a global channel network covering clinics and laboratories. Germany's Sirona originated from the dental division of Siemens Healthcare, holding digital dental assets such as CEREC, CBCT, and intraoral scanners. In 2016, the two companies merged as equals to form Dentsply Sirona, integrating equipment, implants, orthodontics, and endodontic consumables into a single system, becoming the world's largest professional dental product and technology manufacturer.
Milestones
1899
Founding Turning Point
Dentsply was founded in the U.S. in 1899. Dentsply Sirona officially claims over 130 years of dental innovation history. It initially established itself through the distribution of dental consumables and supplies, gradually building a global distribution network covering clinics and laboratories, which laid the channel foundation for its M&A expansion a century later.
1997
Independence and Digital Layout Turning Point
Germany's Sirona became independent from the former Siemens Healthcare dental division and bet on the digital dental track: launching the CEREC chairside CAD/CAM restoration system, oral CBCT, and intraoral scanners, becoming a benchmark manufacturer for global digital dental equipment, providing the equipment and technical assets for the 2016 merger with Dentsply.
2016
Merger of Equals Inflection Point
In 2016, the U.S.-based Dentsply, with over 130 years of history, and Germany's Sirona merged as equals to form Dentsply Sirona, becoming the world's No. 1 professional dental product and technology manufacturer. Post-merger, the product line covers implants (Lance, Ankylos), orthodontics, endodontics, digital imaging, and CAD/CAM, forming a closed loop of equipment and consumables.
2025
Goodwill Impairment Failure
On February 26, 2026, the company announced its Q4 and full-year 2025 results: Q4 net sales were $961 million, up 6.2% YoY, but the full-year net loss was $598 million, including a $650 million impairment of goodwill and intangible assets. The valuation shrinkage of previous M&A assets became one of the heaviest financial burdens in the company's history.
2025
Leadership Change Inflection Point
Dan Scavilla took over as CEO of Dentsply Sirona in the fall of 2025. He previously spent ten and a half years at Globus Medical, serving as CFO, COO, and CEO. About 5 months after taking office, he proposed a focus on core businesses and a turnaround roadmap during the 2026 Q1 earnings call, reshaping the company's strategic priorities.
2026
Turnaround Validation Growth
In Q1 2026, revenue was $880 million, exceeding the market expectation of $843 million, with net loss attributable to shareholders narrowing to $10 million. In Q2, revenue was $898 million, and the gross margin recovered from 48.5% in Q1 to 54.9%. The company maintained its full-year revenue guidance of $3.5 billion to $3.6 billion and adjusted EPS guidance of $1.40 to $1.50.
Turning Points
- The 2016 merger of equals with Sirona propelled the company from a consumables and distributor role to the global leader in all dental categories.
- Sirona's post-independence bet on digital dental equipment like CEREC and CBCT established the technical foundation.
- The $650 million goodwill impairment in 2025 forced the company to restructure its business focus and capital allocation.
- The 2025 leadership change saw Scavilla leverage his Globus Medical background to redefine the 2026 turnaround roadmap.
Failures & Pitfalls
- The $598 million full-year net loss in 2025, compounded by a $650 million goodwill impairment, exposed the financial costs of large-scale M&A.
- In Q1 2026, the net loss attributable to shareholders was $10 million and the gross margin dropped to 48.5%, showing that revenue exceeding expectations could not mask profitability pressures.
- Q1 2026 APAC revenue fell 8.1% YoY, as the China market faced pressure from domestic substitution and VBP, causing the growth engine to stall.
- In the first half of 2026, the company won bids for only 97 dental chairs in Chinese public hospitals, with a market share of about 0.84%, as its premium positioning struggled against the cost-effectiveness strategies of local manufacturers.
关键成功要素
- M&A as the primary growth driver: Since its founding in 1899, the company expanded through continuous acquisitions, culminating in the 2016 merger with Sirona to reach the global top.
- Equipment and consumables bundling: Digital equipment like CEREC and CBCT drive sales of implant, orthodontic, and endodontic consumables, creating a closed loop of repeat purchases from hospitals to clinics.
- Endorsement by German manufacturing: Implant brands like Lance and Ankylos established price gradients and trust in the Chinese market based on their German and European premium clinical history.
- New CEO's 'subtraction' strategy: Since taking office in 2025, Scavilla has focused on core businesses and cost control, driving the gross margin back up from 48.5% to 54.9%.
- End-to-end digital implant solutions are promoted through roadshows and industry exhibitions in China, using clinical education to hedge against price competition.
Lessons
- A merger of equals can quickly achieve industry leadership, but goodwill and integration costs may erode profits years later.
- Revenue exceeding expectations does not equal improved profitability; the Q1 2026 gross margin decline shows that quality of growth is more important than scale.
- A century-old channel and clinical education network in mature markets is harder for new entrants to replicate than a single blockbuster product.
- Facing VBP and domestic substitution, premium brands need to use end-to-end digital solutions rather than simple price cuts to defend market share.
Core Data
- 2026 Q1 Revenue：$880 million (exceeding the expected $843 million) (Based on public data, not independently verified)
- 2025 Full-Year Net Loss：$598 million (Based on public data, not independently verified)
- 2025 Goodwill and Intangible Asset Impairment：$650 million (Based on public data, not independently verified)
- 2026 Q1 APAC Net Sales：$115 million (down 8.1% YoY) (Based on public data, not independently verified)
- 2026 Q2 Gross Margin：54.9% (vs 48.5% in 2026 Q1) (Based on public data, not independently verified)
- 2026 Full-Year Revenue Guidance：$3.5 billion to $3.6 billion (Based on public data, not independently verified)
- 2026 Adjusted EPS Guidance：$1.40 to $1.50 (Based on public data, not independently verified)
- 2026 H1 Chinese Public Hospital Dental Chair Bids Won：97 units, market share approx. 0.84% (Based on public data, not independently verified)
Competitors / Peers
Peer benchmarks include Straumann (Switzerland), Envista (USA), Align Technology (leader in clear aligners), and Planmeca (Finland). Straumann competes directly with Dentsply Sirona in full-cycle implant services and digital diagnostics, while Align Technology occupies the high-profit clear aligner segment. In the Chinese dental chair and equipment market, domestic brands have become dominant; Dentsply Sirona's 97 units won in public hospitals in the first half of the year only ranked first among imported brands, with a market share of about 0.84%, as VBP and domestic substitution continue to pose pressure.